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Functional responses of natural killer (NK) cells including eradication of “harmful” cells
and modulation of immune responses are regulated by a broad variety of activating and
inhibitory NK receptors. Whereas the leukocyte receptor complex (LRC) encodes for NK
receptors of the immunoglobulin superfamily, genes of C-type lectin-like NK receptors are
clustered in the mammalian natural killer gene complex (NKC). Besides the thoroughly
studied C-type lectin-like receptors NKG2D, CD94/NKG2x, and members of the murine
Ly49 subfamily, the NKC also encodes for NK receptors of the less characterized NKRP1
subfamily. The prototypic mouse NKRP1 receptor is Nkrp1c (also known as NK1.1), while
human members of the NKRP1 subfamily are NKRP1A, NKp80, and NKp65. The latter are
not straight homologs of mouse NKRP1 receptors, but share distinct subfamily-specific
traits classifying them as members of the NKRP1 subfamily. Ligands of the human NKPR1
receptors are likewise C-type lectin-like glycoproteins belonging to the CLEC2 subfamily
(i.e., LLT1, AICL, and KACL), and are encoded in the NKC in tight genetic linkage to their
respective receptors. Similarly, certain members of the mouse NKRP1 subfamily interact
with genetically coupled CLEC2 glycoproteins, while the reasons for this intriguing tight
genetic linkage remain unknown. Recent studies provided new and unique insights into
the expression, interaction, and signaling of NKRP1 receptors and their ligands, thereby
substantially advancing our understanding of their function and biology. Here, we review
our current knowledge on NKRP1 receptors and their genetically linked CLEC2 ligands
with an emphasis on the human receptor/ligand pairs NKRP1A-LLT1, NKp80-AICL, and
NKp65-KACL.
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STRUCTURE AND FUNCTION OF NK CELL RECEPTORS
Natural killer (NK) cells perform diverse functions: they not
only eradicate virus-infected, malignantly transformed, or stressed
cells by virtue of their cytotoxic capabilities, but also produce
chemokines and cytokines such as IFNγ, thereby modulating
immune responses and contributing to tissue homeostasis (1–4).
To serve this variety of purposes, NK cells express a plethora
of germline-encoded activating and inhibitory receptors that, in
concert, regulate their activities (5–7).
There are two main structural classes of NK receptors with the
respective genes clustered at two distinct sites in the mammalian
genome: NK cell receptors of the C-type lectin-like superfamily,
which will be discussed in detail in this review, are encoded in
the natural killer gene complex (NKC; human chromosome 12),
whereas the leukocyte receptor complex (LRC; human chromo-
some 19) codes for immunoglobulin (Ig)-like NK cell receptors
(8, 9). Inhibitory NK receptors ligating classical major histo-
compatibility complex (MHC) class I molecules are either LRC-
encoded [e.g., killer cell Ig-like receptors (KIR) in humans] or
NKC-encoded (e.g., C-type lectin-like Ly49 receptors in rodents)
depending on the respective mammalian order (8, 10). These mol-
ecular MHC class I sensors allow the release of NK cell cytotoxicity
toward MHC class I-deficient cells typically arising upon viral
infection or during tumor formation, and, hence, represent the
molecular substrates of the “missing-self” recognition mode (10–
12). In contrast, most activating NK cell receptors are conserved
among mammalians such as the LRC-encoded Ig-like natural cyto-
toxicity receptor (NCR) NKp46 and the NKC-encoded, ligand-
promiscuous C-type lectin-like receptor (CTLR) NKG2D (9, 13,
14), that both enable molecular recognition of malignant or
infected cells by NK cells. In addition to NKG2D and Ly49 recep-
tors, the mammalian NKC encodes for several dozens of other
CTLR expressed by various types of hematopoietic cells including
NK cells, with some of these CTLR still being poorly explored (9).
C-TYPE LECTIN-LIKE NK RECEPTORS ENCODED IN THE
NATURAL KILLER GENE COMPLEX
The immune-related CTLR of the NKC have been classified as
CTLR of the subgroup V within the realm of multiform C-
type lectins (15, 16). This subgroup comprises atypical C-type
lectins that have lost the ability to bind carbohydrates via Ca2+
complexation and instead interact with proteins as their natural
ligands (9, 16). They are type II transmembrane glycoproteins with
an aminoterminal cytoplasmic domain, a single transmembrane
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domain followed by a stalk region and a single extracellular C-
type lectin-like domain (CTLD) at the carboxyterminus (9, 16).
This name-giving CTLD basically is built up by two α-helices and
two antiparallel β-sheets creating a compact structure that is stabi-
lized by two or (mostly) three conserved intramolecular disulfide
bonds. Another typical feature is the “WIGL” motif, a stretch of
four hydrophobic amino acids that forms the core of the CTLD (9,
16). Functional NKC-encoded CTLR usually form homo- or het-
erodimers disulfide-linked via paired cysteines of the stalk region
that – like the cytoplasmic domain – exhibits considerable length
variations among NKC-encoded CTLR.
Natural killer cell-encoded CTLR have been classified based
on the expressing cell type either as killer cell lectin-like recep-
tors (KLR) for NK cell-associated CTLR or C-type lectin receptors
(CLEC) expressed by non-NK cells.
NKC-ENCODED NK RECEPTORS BIND EITHER MHC CLASS
I-LIKE OR C-TYPE LECTIN-LIKE LIGANDS
Most NK cell-associated CTLR (KLR) are known to bind glyco-
proteins with an MHC class I-like fold: these include classical and
non-classical MHC class I molecules, and MHC class I-like mol-
ecules (Figure 1). A prominent member of this group is NKG2D
(KLRK1), an activating receptor that binds to several MHC class
I-like molecules induced by various forms of cellular stress such
as viral infection, tumor formation, tissue damage, and heat shock
(17, 18). Another example are the murine Ly49 receptors detecting
allelic variants of MHC I molecules and the CD94/NKG2x recep-
tors interacting with a non-classical MHC class I molecule present-
ing signal peptides of MHC class I molecules (9, 12) (Figure 1).
These NK receptors share their MHC class I ligands with T cell
receptors (TCR) of cytotoxic T cells. According to current belief,
this molecular partner-sharing between TCR of CD8 T cells and
MHC class I-specific inhibitory receptors of NK cells primarily
evolved owing to the evolutionary imperative to bail the adap-
tive immune system out of its MHC-centric single-mindedness,
i.e., establishing “missing-self” recognition of NK cells as a safe-
guard for CD8 T cell-blinding in case of abrogated MHC class I
expression.
In a distinct subregion of the mammalian NKC, there is a
gene cluster of a second class of KLR comprising members of
the NKRP1 (NK receptor protein) subfamily. In contrast to other
KLR, these NKRP1 receptors do not bind MHC class I-like ligands.
The prototypic NKRP1 family member is the mouse activating
receptor Nkrp1c (NK1.1) representing one of the earliest reported
FIGURE 1 | Ligands of NKC-encoded C-type lectin-like NK cell
receptors: C-type lectin fold versus MHC class I fold. (A,B) NK cell
receptors encoded in the human (A) or in the mouse NKC (B) engage
two structural types of ligands: ligands of NK cell receptors of the
NKRP1 subfamily likewise are C-type lectin-like receptors and members
of the CLEC2-subfamily encoded in tight genetic linkage to their
respective receptors in the NKC (left). Ligands of Nkrp1a, Nkrp1c, Clr-a,
Clr-h, and CD69 remain to be identified. Ligands of CD94/NKG2x
receptors and Ly49 receptors (mouse only) are MHC class I complexes
consisting of a heavy chain, β2-microglobulin, and a peptide (right). The
activating NKG2D receptor binds multiple ligands related to the MHC
class I heavy chain not associated with β2-microglobulin or antigenic
peptides (middle). Symbols “+” and “−” indicate activating and
inhibitory function, respectively, of the respective receptors as reported.
For Nkrp1a, Nkrp1f, and Nkrp1g, functional consequences of receptor
triggering remain to be addressed.
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markers of mouse NK cells (19). While the ligand (and thus the
function) of Nkrp1c still remains elusive, other NKRP1 receptors
in mouse, rat, and man have been shown to engage structurally
highly related CTLR belonging to the CLEC2 subfamily whose
genes are interspersed in the NKC among the NKRP1 genes (20,21)
(Figure 1). In mice, most CLEC2 family members are represented
by C-type lectin-related (Clr) molecules (Clr-a,-b,-c,-d,-f,-g,-h)
(20). Originally, the mouse receptors Nkrp1d and Nkrp1f have
been shown to engage the genetically linked Clr molecules Clr-b
and Clr-g, respectively, and Nkrp1d/Clr-b interaction has been
proposed to represent another form of “missing-self” recogni-
tion, as Clr-b expression was often diminished on tumor cell
lines (22, 23). Another rather prominent representative of the
CLEC2 family is CD69 (CLEC2C): CD69 is well-known for its
rapid cell-surface appearance on lymphocytes upon activation
(24) and has been involved in the retention of activated lym-
phocytes in lymphoid organs by virtue of a cis interaction with
sphingosine-1-phosphate receptor 1 (25). As for Nkrp1c (NK1.1),
a trans-acting receptor of CD69 has not yet been identified. CD69
is the only CLEC2 family member conserved both in man and
rodents. Other human CLEC2 family members are “keratinocyte-
associated C-type lectin” (KACL; encoded by the CLEC2A locus),
“activation-induced C-type lectin” (AICL; CLEC2B), and “lectin-
like transcript 1”(LLT1; CLEC2D) (Figure 2A) that are equidistant
relatives of mouse Clr molecules and share CLEC2-subfamily traits
such as the“FLkRy”motif in theα2 helix (for dimerization),a short
FIGURE 2 | Modulation of NK cell responses by C-type lectin-like
receptor/ligand pairs encoded in the human NKC. (A) NKRP1 receptors
and their respective ligands of the CLEC2 subfamily are encoded in tight
genetic linkage in the telomeric subregion of the human NKC on chromosome
12. Genes (italics) are depicted true to scale with transcriptional orientations
indicated by arrows and receptor-ligand pairs by dashed lines. (B) NKRP1A
inhibits cytotoxicity and IFN-γ secretion of NK cells upon binding of LLT1
expressed on activated leukocytes. In contrast, NKp80 stimulates effector
responses of NK cells: NKp80-AICL interaction promotes TNF and IFNγ
production in an activating cross-talk between NK cells and monocytes in the
presence of inflammatory cytokines. Further, “resting” NK cells also respond
to monokine-activated NK cells in an NKp80-dependent manner by cytokine
secretion and cytotoxicity: AICL surfaces on activated NK cells from stores in
the Golgi complex, rendering these susceptible to NKp80-mediated cytolysis
by bystander NK cells. (C) NKp65 stimulates cytotoxicity and IFNγ secretion
of NK-92 cells upon encounter of KACL-bearing target cells. While KACL is
specifically expressed by keratinocytes of the human epidermis, cells
endogenously expressing NKp65 remain undefined.
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L3 loop, and a frequent replacement of CTLD cysteines 4 and 5,
which are highly conserved in other CTLR (21). These CLEC2
family members are ligands of the human NK receptors NKp80,
NKp65, and NKRP1A (or CD161) that do share a couple of unique
features as outlined in the following chapters and therefore rea-
sonably can be grouped as human NKRP1 receptors. It should be
noted, however, that among these, NKRP1A is most closely related
to mouse NKRP1 receptors.
GENETICALLY LINKED NKRP1 RECEPTOR-CLEC2 LIGAND
PAIRS IN THE HUMAN NKC
The three human CLEC2 glycoproteins LLT1, AICL, and KACL
specifically bind to the respective close-by encoded human NKRP1
receptors with the inhibitory CTLR NKRP1A (encoded by the
KLRB1 locus) ligating LLT1, and the activating receptors NKp80
(KLRF1) and NKp65 (KLRF2) binding to AICL and KACL, respec-
tively (Figures 1 and 2) (26, 27). The reasons for this characteristic
tight genetic linkage of NKRP1 receptor-CLEC2 ligand pairs are
unknown, but certainly are of considerable interest for a thorough
understanding of their functional relevance. Notably, no criss-
cross-reactivity has been detected between these human NKRP1
receptors and other CLEC2 family members in binding assays with
the respective purified CTLD apart from their above-mentioned
dedicated interaction (26). This is different for certain members
of the mouse NKRP1 receptors, some of which have been reported
to promiscuously bind to several Clr molecules: e.g., Nkrp1f binds
to Clr-c, Clr-d, and Clr-g, while Nkrp1g binds to Clr-d, Clr-f, and
Clr-g (23, 28, 29). Crucial insights into specificity and promiscuity
of NKRP1–CLEC2 interactions can be expected from analyses of
crystal structures as described in the following.
INTERACTION OF LOOK-ALIKES: STRUCTURAL ASPECTS OF
NKRP1–CLEC2 INTERACTION
Up to date, several crystal structures of NKC-encoded CTLR in
complex with MHC class I-like ligands have been solved such as
the NKG2D/MICA complex (30), CD94/NKG2A bound to HLA-E
(31, 32), and mouse Ly49A in complex with its MHC class I ligand
H-2Dd (33).
In contrast, the mode of interaction of NKRP1-CLEC2 pairs
remained unknown, as only unligated structures of NKRP1 [i.e.,
Nkrp1a (34)] or CLEC2-subfamily members [i.e., CD69 (35, 36),
and Clr-g (37)] have been reported. However, the first struc-
ture of a NKRP1-CLEC2 receptor/ligand pair became available
very recently showing NKp65 in complex with its ligand KACL,
also representing the first complex structure of two interacting
CTLD (38).
The complex of NKp65/KACL reveals a KACL homodimer that
symmetrically binds two NKp65 monomers in a bivalent binding
mode, i.e., one NKp65 monomer is bound by each KACL subunit
in an identical manner. Both, NKp65 and KACL are structurally
very similar (CTLD sequence identity: 29%) and interact via the
membrane-distal surface of the CTLD in a head-to-head orienta-
tion. Hence, binding of a KACL subunit to an NKp65 monomer
resembles a symmetrical homodimer (38). It has been noted that
this symmetrical, butterfly-shaped assembly of the NKp65/KACL
complex exhibits some similarities with the Ly49C/H-2Kb com-
plex in which the dimeric Ly49C receptor interacts with two MHC
class I ligands (39). Contrary to this, other NKC-encoded recep-
tors such as NKG2D, CD94/NKG2A, and Ly49A follow a different
binding mode in which a dimeric CTLR engages only a single
MHC class I(-like) molecule.
The large interface of the NKp65-KACL complex is mainly
hydrophobic, contains numerous hydrogen bonds and stands
out due to a high shape complementarity (38). Collectively,
these features explain the exceptionally high affinity in the low
nanomolar range that also may compensate for the monomeric
state of NKp65 (38). Differently from the two other human
NKRP1-CLEC2 receptor-ligand pairs, neither NKp65 nor KACL
are disulfide-linked. Originally, homodimerization was proposed
for both, NKp65 and KACL (26), but the crystal structure of the
NKp65-KACL complex reveals a monomeric NKp65, while con-
firming homodimerization of KACL (38). The comparison of the
structures for KACL, human CD69, and mouse Clr-g shows a
very similar dimerization mode of the CTLD with the two sub-
units primarily interacting through the β0 strand and the α2 helix
(35–38).
As the sequence relatedness of the CTLD of KACL, AICL,
LLT1, and mouse Clr molecules as well as that of the mouse
and human NKRP1 receptors suggest a high structural similar-
ity, the NKp65-KACL structure was proposed to be representa-
tive for all genetically linked NKRP1-CLEC2 pairs encoded in
the NKC (38). Mariuzza and colleagues define five key binding
residues of KACL in the interaction with NKp65 that are either
highly conserved or conservatively substituted among all three
related human CLEC2 glycoproteins (KACL, AICL, and LLT1)
(38). Notably, these amino acids make contact to residues of the
respective receptors (NKp65, NKp80, and NKRP1A) which, them-
selves, are either strictly conserved or conservatively substituted.
Consequently, these key binding residues might drive the interac-
tion of NKC-encoded receptor/ligand pairs to adopt a conserved
binding topology, while specificity of a receptor for a certain lig-
and may be determined by additional, less conserved amino acids
in the binding interface. Based on structural data or mutational
analyses, other previous studies suggested an interaction mode for
certain NKRP1-CLEC2 receptor/ligand pairs (i.e., Nkrp1f/Clr-g;
NKRP1A-LLT1) primarily based on electrostatic complementarity
(37, 40).
ENGAGEMENT OF LLT1 BY NKRP1A MODULATES IMMUNE
RESPONSES
An early report by Lanier and colleagues characterized the
NKRP1A receptor as a human homolog of mouse inhibitory
Nkrp1 receptors expressed as a disulfide-linked homodimer on
most human NK cells (41). In the following, NKRP1A expres-
sion was also reported for NKT cells, various subsets of T cells
including Th17 cells, as well as groups of innate lymphocytes (42–
46). The seminal report by Yokoyama and colleagues of certain
mouse NKRP1 receptors engaging ligands of adjacently encoded
Clr molecules (23) also stimulated the research on ligands of
human NKRP1 receptors resulting in the identification of LLT1
as the ligand of NKRP1A (47, 48). LLT1 is the product of one out
of several alternatively spliced transcripts of the CLEC2D locus,
and is primarily expressed on activated lymphocytes and antigen
presenting cells such as Toll-like receptor (TLR)- or B cell receptor
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(BCR)-activated B cells (49–51). LLT1 expression on antigen pre-
senting cells is enhanced by IFNγ and inducible on B cells by
infection with HIV or Epstein–Barr virus, as well as in inflamed
tonsils (50). When bound by LLT1, NKRP1A inhibits cytotox-
icity and IFNγ production of NK cells thus impairing NK cell
responses toward B cells (Figure 2B) (47, 48). Expression of LLT1
on TLR-stimulated plasmacytoid and monocyte-derived dendritic
cells (DC) might, at least in parts, explain the resistance of mature
DC toward NK cell-mediated cytolysis (51).
Overall, NKRP1A-LLT1 interaction may contribute together
with the MHC class I-specific inhibitory receptors and
CD94/NKG2A to NK self-tolerance. Along these lines, it has
been proposed based on studies with glioblastoma, that aberrant
expression of LLT1 is exploited by malignant cells to avert NK
cell-mediated tumor elimination (52).
While NKRP1A clearly functions as an inhibitory receptor on
NK cells, the role of NKRP1A on T cells appears ambiguous as
evident from a series of studies by various laboratories: NKRP1A
engagement has been reported to costimulate T cell proliferation
and cytokine secretion by activated T cells (47, 50, 53), to provide
costimulation for NKT cells (42), but also to reduce release of TNF
by CD8 T cells (51). Obviously, NKRP1A ligation differentially
impacts on NK and T cell function in vitro, while the immunolog-
ical significance of NKRP1A engagement by LLT1 for the various
NKRP1A-expressing lymphocytes in vivo remains poorly under-
stood. Studies on NKRP1A signaling cascades in NK versus T cells,
as well as in vivo studies with humanized mice may be suitable to
further our understanding of NKRP1A function.
IMMUNOMODULATORY FUNCTIONS OF NKp80-AICL
INTERACTION
The disulfide-linked homodimeric CTLR NKp80 originally was
identified by Moretta and colleagues as an activating receptor
rather specifically expressed by human NK cells (54). Subsequent
studies showed that NKp80 is conserved among primates but
absent from rodents (55, 56) and also present on certain γδ T
cells as well as a subset of effector memory CD8 αβ T cells that
are characterized by high cytotoxic responsiveness and an inflam-
matory NK-like phenotype (27, 57). In contrast to the expression
on virtually all human NK cells, NKp80 expression is absent from
human NK cell lines (58).
Activation-induced C-type lectin was uncovered as an NKp80
ligand when pursuing the hypothesis that receptor and ligand
may be encoded in genetic linkage (27). Indeed, the genes of
NKp80 and AICL are located in a tail-to-tail orientation only
7 kb apart from each other (27) (Figure 2A). An earlier report
on the induction of AICL transcripts upon activation of periph-
eral blood mononuclear cells led to the term AICL (59). Later,
expression of AICL glycoproteins was observed for myeloid cells,
including macrophages, granulocytes, and TLR-stimulated mono-
cytes, while differentiation of monocytes to DC is accompanied by
a concomitant decrease in AICL expression (60).
Functional studies characterized NKp80 as an activating NK
cell receptor triggering cytotoxicity and promoting the release of
the proinflammatory cytokines IFNγ and TNF (27, 54). AICL is
expressed on some human myeloid cell lines, most prominently
on U937 (27, 54), and expression by a few non-hematopoietic cell
lines and primary human liver cancer cells has also been reported
(61). Accordingly, NKp80-AICL interaction stimulates cytolysis of
malignant AICL-expressing myeloid cells by NK cells and effector
memory CD8 T cells (27, 57). These findings raise the possibility
that NKp80-AICL interaction may contribute to NK-mediated
surveillance of myeloid leukemia cells. Notably, cells infected
with Kaposi’s sarcoma-associated herpes virus (KSHV) have been
shown to downregulate AICL through the action of a viral ubiqui-
tin ligase, thereby providing protection against NKp80-mediated
cytotoxicity (62). Possibly, a similar mechanism of AICL retention
or downregulation may also be exploited by malignant cells.
NKp80-AICL interaction not only promotes NK cell-mediated
cytolysis of malignant myeloid cells, but also is critically involved in
the mutual activating cross-talk between NK cells and monocytes
under inflammatory conditions stimulating secretion of IFNγ
and TNF, respectively (27, 63) (Figure 2B). Similarly, contribu-
tion of NKp80 to the mutual activation of effector T cells and
macrophages under inflammatory conditions was observed (57).
Hence, NKp80-AICL interaction may be involved in the induc-
tion and modulation of immune responses during the early phase
of infection or maintenance of immune responses during chronic
inflammation.
Only very recently, AICL expression by primary human NK
cells was reported (58). In resting NK cells, AICL glycoproteins are
retained in the Golgi complex primarily due to unresolved interac-
tions of its CTLD. Intracellular retention has also been observed for
CD69 expressed by resting lymphocytes while cellular activation
led to a rapid mobilization of CD69 to the cell surface (64). Simi-
larly, AICL surfaces on NK cells activated upon PMA-treatment or
exposure to monokines IL-12 and IL-18 (58). Monokine-induced
AICL expression on human NK cells is paralleled by downregula-
tion of NKp80 leading to a loss of NKp80-mediated responsive-
ness. Instead, AICL expression on monokine-activated NK cells
enabled functional recognition by autologous “resting” NK cells
in an NKp80-dependent manner stimulating cytokine produc-
tion and cytotoxicity of the latter (Figure 2B). As memory-like
properties of NK cells are induced by exposure to monokines
IL-12 and IL-18 (65), e.g., in secondary lymphoid organs and
at sites of inflammation, one might hypothesize that upregula-
tion of AICL and subsequent NKp80-mediated elimination of
monokine-activated NK cells by bystander NK cells contributes
to the regulation of the pool of “memory” NK cells. Activated NK
cells have previously also been shown to upregulate LLT1 at the
cell surface (50) and, hence, a simultaneous engagement of LLT1
by NKRP1A may diminish the activating signals emanating from
NKp80 engagement through AICL on activated NK cells.
Of note, human NK cells not only express NKp80 but also the
NKp80 ligand AICL, thereby allowing for an autonomous con-
trol of human NK cell responses. The observed co-expression of
AICL and its receptor NKp80 by the same cell type sheds new
light on the tight genetic linkage of NKC-encoded NKRP1/CLEC2
receptor/ligand pairs that might allow for an interdependent reg-
ulation of gene expression at the transcriptional level. Limitation
of cellular immune responses by NK cells has also previously been
reported for NKG2D-mediated recognition and cytolysis of acti-
vated T cells (66) and, along these lines, it is of interest whether
AICL also is upregulated on activated T cells and B cells.
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KACL AND ITS ACTIVATING RECEPTOR NKp65 FACILITATE
IMMUNOSURVEILLANCE OF KERATINOCYTES
The CTLR encoded by the CLEC2A gene was termed KACL (for
keratinocyte-associated C-type lectin) due to its almost exclusive
expression by human keratinocytes (67). This rather skin-specific
expression of KACL is unique among human and mouse CLEC2
family members: several of these are commonly expressed by
hematopoietic cells (e.g., LLT1, AICL, CD69, Clr-g), while others
exhibit either a very broad (e.g.,Clr-b) or a highly restricted expres-
sion by epithelial or neuronal tissues (e.g., Clr-f, BACL) (21, 68,
69). Specific expression of KACL by keratinocytes may be indica-
tive for a dedicated role in skin immunobiology, but such a role
remains to be shown in context of expression and function of the
KACL receptor NKp65 (see below). As KACL is also prominently
expressed by the myeloid cell line U937 and residual KACL tran-
scripts were detected in bone marrow, expression by a scarce subset
of hematopoietic cells cannot be excluded (67).
Analogous to the genetic linkage of the two related human
NKRP1-CLEC2 pairs NKRP1A-LLT1 and NKp80-AICL, the
KLRF2 gene coding for the KACL receptor NKp65 is situated
in close proximity to CLEC2A in the NKC with both genes only
3 kb apart in a tail-to-tail orientation (26) (Figure 2A). As men-
tioned earlier, NKp65 binds to KACL with very high affinity
(K D∼ 1–10 nM) (26, 38). Hence, the NKp65-KACL interaction
is among the strongest known between cell-bound receptors,
and considerably stronger than NKp80-AICL (K D∼ 4µM) and
NKRP1A-LLT1 (K D∼ 48µM) interactions (26, 27, 38, 40). Func-
tional engagement of NKp65 by KACL-expressing transfectants
or keratinocytes stimulates effector responses such as cytotoxi-
city and IFNγ release by the human NK cell line NK-92 (26)
(Figure 2C) showing that NKp65 is an activating receptor that
facilitates immunosurveillance of human keratinocytes. However,
significant expression of NKp65 has so far only been detected for
NK-92 cells, while peripheral blood NK cells only contain trace
amounts of NKp65 transcripts (26, 38). Hence, cells physiologi-
cally expressing NKp65 remain to be identified in order to attribute
functional relevance to the NKp65-KACL system and to address a
potential involvement in diseases of the skin such psoriasis or even
in wound healing.
MECHANISMS OF SIGNALING BY HUMAN NKRP1
RECEPTORS
Most NK receptors transduce signals through a couple of tyrosine-
based sequence motives with the tyrosine being phosphorylated
upon ligand engagement and acting as a starting point of the
emerging signaling cascade. The widespread immunoreceptor
tyrosine-based activating motif (ITAM) consists of a tandem tyro-
sine unit with two YxxL modules separated by six to eight amino
acids and ITAM-based signaling is a common mechanism in acti-
vation of T cells, B cells, and NK cells (7, 70). Usually, ITAM are part
of specialized signaling adaptors, variably associating with lym-
phocyte receptors, thus secluding ligand engagement from signal
transduction. In contrast, an activating signaling motif contain-
ing only one such tyrosine module, thus termed hemITAM, has
been described for the cytoplasmic domain of only a few, mostly
myeloid CTLR with ligand binding and initiation of signaling
being executed by the identical polypeptide chain (71, 72). The
same is true for inhibitory receptors containing immunoreceptor
tyrosine-based inhibitory motives (ITIM) in their respective cyto-
plasmic domains: these ITIM relay inhibitory signals through
recruitment of phosphatases that finally dampen or abrogate
activating signals (7, 70).
Some activating C-type lectin-like NK cell receptors such
as Ly49H and CD94/NKG2C associate with the ITAM-bearing
adapter molecule DNAX-activating protein of 12 kDa (DAP12)
through charged interactions in their transmembrane domains
(5, 73). Other ITAM-bearing adaptor molecules employed by NK
cells are CD3ζ or FcεRIγ associating with the NCR NKp30 and
NKp46, the low-affinity Fc receptor CD16, or Nkrp1c (NK1.1) (5,
73). ITAM signaling in NK cells involves phosphorylation by Src
family kinases and subsequent recruitment and activation of tyro-
sine kinases Syk and ZAP-70 that, in turn, signal downstream via
phosphatidylinositol-3-kinase (PI3K), phospholipase Cγ (PLCγ),
and Vav family members (5, 73). Of note, the CTLR NKG2D
almost uniquely associates with DAP10 that contains a YINM
motif, triggering cytotoxicity in a Syk-independent mechanism
through recruitment of PI3K and a Grb2-Vav1 complex (73, 74).
Signaling is rather different for the human activating NKRP1
receptors NKp80 and NKp65 that do not associate with ITAM-
containing signaling adaptors such as DAP12. Instead, the cyto-
plasmic domain of both, NKp80 and NKp65, contains a hemITAM
(26, 75) initially described for myeloid-specific CTLR such as
CLEC-2 and Dectin-1 (72, 76) (Figure 3). The aminoterminal
hemITAM of these CTLR variably matches the consensus sequence
DGYxxL with the phosphorylatable tyrosine located at position 7
in all receptors except for Dectin-1 (72). The hemITAM is also con-
sistently situated at a certain distance to the plasma membrane in
all CTLR for yet unknown reasons. While the hemITAM-bearing
CTLR in myeloid cells stimulate phagocytosis and cytokine secre-
tion, ligation of NKp80 and NKp65 triggers cytotoxic responses
by the NK-92 cell line in a hemITAM-dependent manner (26, 75).
The hemITAM of CLEC-2 and Dectin-1 have both been shown
to recruit and transduce signals through Syk (77–79). With the
sequence ERYxxL, the hemITAM of NKp80 significantly differs
from the consensus and therefore was classified as an “anom-
alous hemITAM” (75). Arginine 6 was shown to contribute to
a less effective phosphorylation of NKp80, while both glutamate
5 and arginine 6 impaired Syk recruitment resulting in a damp-
ened NKp80-mediated responsiveness (80). The latter could be
enhanced by reconstitution of the consensus hemITAM sequence
or Syk overexpression (80). As glutamate 5 and arginine 6 are
largely conserved among mammalian NKp80 sequences, it has
been speculated that dampening of the NKp80-mediated NK
cell activation of NK cells evolved to mitigate cytotoxic NK cell
responses toward AICL-expressing leukocytes (80).
Syk binding to hemITAM sequences has been studied intensely
for CLEC-2 which is only active as a non-disulfide-linked
homodimer (81). The molecular mechanisms of CLEC-2 activa-
tion seem to be different from that described for ITAM activation
since initial phosphorylation of CLEC-2 rather depends on Syk
kinase activity than on Src family kinases (82, 83). Thereby, Syk
is reported to cross-link CLEC-2 monomers via its tandem SH2
domains (77). This hemITAM cross-binding mode reflects the lack
of a second YxxL module in the same polypeptide chain, and may
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FIGURE 3 | Signaling modules of human NKRP1 receptors.
(A) ITAM-bearing adaptors such as DAP12 are tyrosine phosphorylated
upon ligand binding of the associated receptor chain and subsequently
recruit Syk kinases via their SH2 domains (left). CLEC-2 is a prototypical
hemITAM-containing CTLR expressed by myeloid cells where two
juxtaposed and phosphorylated hemITAM are thought to recruit Syk
kinase, thereby bridging two adjacent CLEC-2 monomers. The
aminoterminal sequences of both, NKp65 and NKp80, comprise a
hemITAM-like sequence with tyrosine 7 being essential for signaling.
However, Syk binding to NKp65 remains to be shown and recent studies
with NKp80 suggest preferred recruitment of a yet unknown signaling
protein different from Syk. (B) Sequence alignment of
hemITAM-containing human activating CTLR expressed by NK cells
(NKp80), myeloid cells (CLEC-2, Dectin-1, DNGR-1), or yet unknown cells
(NKp65), and of ITIM-containing receptors NKRP1A (human) and Nkrp1b
(mouse). The core motifYxxL of both hemITAM and ITIM is bolded, the
hemITAM-preceding triacidic amino acid sequence underlined, and the first
amino acids of the transmembrane domains are in italics. Sequence gaps
introduced for alignment are denoted by dashes. HemITAM and ITIM
consensus (Ω=L/V/I/S) sequences are also given.
even represent the evolutionary forerunner of an “outsourced”
ITAM signaling by secluded and highly specialized adaptor chains
with two coupled YxxL modules. Moreover, the triacidic amino
acid sequence (DED motif preceding the YxxL motif in CLEC-2;
Figure 3B) was shown to be crucial for Syk-dependent signal-
ing (82). Yet, in NKp80, arginine 6 may attenuate these negative
charges and thus modulate NKp80 signaling capacity.
The inhibitory mouse Nkrp1b receptor comprises an ITIM in
its cytoplasmic domain which recruits Src homology 2-containing
protein tyrosine phosphatase-1 (SHP-1) in a phosphorylation-
dependent manner (84), and a CXCP motif associated with Lck
recruitment (85). In contrast, Lck recruitment of the human
NKRP1A receptor is controversial (42, 86) and an association with
phosphatases has not been reported so far. Taking this lack of
information and the rather heterogeneous functionality reported
for NKRP1A (see above) into account, a thorough elucidation of
NKRP1A signaling in NK cells and T cells appears necessary. Of
note, human NKRP1A has been shown to stimulate activity of acid
sphingomyelinase leading to ceramide production and subsequent
activation of Akt (53).
Taken together, the activating receptors NKp80 and NKp65,
as compared to other human NK receptors, employ distinct and
unique signaling mechanisms to stimulate NK cell responses.
These mechanistically distinct signaling processes broaden the
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versatility of NK cells to differentially respond to diverse activat-
ing signals in a context-specific manner. Future work will have to
characterize the signaling units interacting with the single tyro-
sine signaling modules of NKp80, NKp65, and NKRP1A, and the
emerging downstream signaling pathways.
SIGNALING BY CLEC2 FAMILY MEMBERS
Several studies also reported signaling capacity for NKC-encoded
CLEC2 family members. For example, cross-linking of CD69 was
reported to trigger cytotoxicity by NK and T cells (87) and to
activate Syk in a Src family kinase-dependent manner, which was
indispensable for PLCγ and Vav1 phosphorylation (24, 88). Since
CD69 contains no tyrosine in the cytoplasmic domain as well
as no charged amino acids in the transmembrane domain for
recruitment of signaling adaptors, tyrosine-based signal trans-
duction appears unlikely. However, signals may be generated
by serine/threonine phosphorylation as reported for DNAM-1
where protein kinase C-mediated serine phosphorylation was
shown to be critical for ligand binding and signaling (89). In T
cells, CD69 association with JAK3/STAT5 was reported to con-
trol Th17 cell differentiation (90). However, a mechanistic link
between JAK/STAT signaling pathways and NK cell cytotoxicity is
lacking.
Cross-linking of AICL was also shown to trigger TNF secre-
tion in monocytes activated with LPS in a manner comparable
to TREM-1 ligation (27) suggesting signaling potential of AICL.
Analogous to human NKRP1 family members, AICL lacks posi-
tively charged residues in the transmembrane domain that seems
to preclude association with ITAM-containing adaptors. The very
short cytoplasmic domain of AICL is composed of only seven
amino acids and does not offer an obvious signaling motif apart
from a single threonine residue that may be subject to phosphory-
lation. Consequently, mechanisms relaying signals through AICL
remain elusive.
CONCLUDING REMARKS
The NKC of both man and mouse encodes for genetically tightly
coupled CTLR/ligand pairs consisting of activating or inhibitory
NKRP1 receptors and various CLEC2 ligands with a highly diver-
sified tissue expression. As of today, the NKRP1 and CLEC2 fam-
ilies still comprise a couple of orphan CTLR, including Nkrp1c,
Nkrp1a, Clr-a, and CD69, where trans-acting ligands remain to be
identified for studies on their functional relevance. These recep-
tor/ligand pairs of mice (i.e., Nkrp1/Clr pairs) and humans (i.e.,
NKRP1A-LLT1, NKp80-AICL, NKp65-KACL) not only share the
genetic linkage, but also other characteristics such as structural
similarities of the CTLD (among NKRP1 receptors and CLEC2
ligands, respectively), related immunoreceptor tyrosine-based sig-
naling motifs in the cytoplasmic domains of the NKRP1 recep-
tors (and the lack of these in the CLEC2 ligands), a preferential
expression of NKRP1 receptors by NK and/or T cells, and CLEC2
ligands with a highly variegated tissue expression, including highly
tissue-specific expression patterns (e.g., KACL, Clr-f).
Referring to the tight genetic linkage, it was originally hypoth-
esized that these NKRP1 receptor-CLEC2 ligand pairs might
have evolved from an ancient histocompatibility system indepen-
dent of the MHC-based immunosurveillance system (23). The
more recently recognized tissue-specific expression of some of
these CLEC2 ligands adds an interesting and supportive facet to
this hypothesis, as certain NKRP1 receptor-CLEC2 ligand pairs
may have specifically evolved to survey rapidly renewing and
pathogen-exposed epithelial barriers (91). Also, specific immuno-
surveillance of activated (and proliferating) hematopoietic cells,
as emerging for the NKp80-AICL system, may go along the same
lines.
Collectively, the present, yet rather basic knowledge on these
genetically coupled CTLR receptor/ligand units suggests an
involvement for some of these in an immunomodulatory cross-
talk between hematopoietic cells whereas others may contribute
to epithelia-specific immunosurveillance, a hypothesis that awaits
to be tested by future research.
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